Pharmacologic Androgen Deprivation and Cardiovascular Disease Risk Factors: a Systematic Review. By Romo et al. 2015 

Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. By Garcia-Albeniz et al 2015 

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. By Ludwig et al 2015 

Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. By Klotz et al 2015

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. By Zapatero et al 2015

Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. By Lassemillante et al 2015

Safety of antiandrogen therapy for treating prostate cancer. Expert opinion on drug safety. By Ricci et al 2014

Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial. By Winters-Stone et al 2015

Subjective and Objective Effects of Androgen Ablation Therapy on Voice. By Salturk et al 2015

The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer. By Jaswal and Crook 2015